低分子肝素联合缬沙坦对2型糖尿病肾病患者UAER的影响

Impact of low molecular heparin and valsartan on urine albumin excretion rate in patients with early type-2 diabetic nephropathy

目的观察低分子肝素联合缬沙坦对2型早期糖尿病肾病(DN)患者尿白蛋白排泄率(UAER)的影响。方法将60例2型早期DN患者随机分为治疗组(n=30):应用低分子肝素联合缬沙坦治疗;对照组(n=30):仅用缬沙坦,检测两组患者治疗前、后UAER及收缩压(SBP),舒张压(DBP),空腹血糖(FPG),糖化血红蛋白(HbA1c)等指标。结果治疗后两组患者的UAER均比治疗前显著降低(P<0.01),尤以实验组降低为明显(P<0.05);治疗前、后两组患者FPG、HbA1c、SBP和DBP相比均无统计学意义(P>0.05)。无出血等不良反应。结论低分子肝素联合缬沙坦能显著降低2型早期DN患者UAER,两者联合应用有协同作用。

Objective To investigate the impact of low molecular heparin （LMH） and valsartan on urine albumin excretion rate （UAER） in patients with early type - 2 diabetic nephropathy （ DN）. Methods Sixty patients with early type - 2 DN were randomly divided into experiment group and control group each consisted of 30 cases. Patients in experiment group were treated with valsartan （p.o） and LMH （s.c）. Patients in control group were treated with valsartan （p.o） only. The blood pressure （BP）, fasting plasma glucose （FPG）, glyocosylated HbA1 （HbA1c） and urine albumin excretion rate （UAER） were monitored before and after treatment. Results UAER after treatment were significantly lower than that before treatment in both experiment and control groups, showing statistically significant differences （P 〈 0.01）. After treatment, UAER in patients of experiment group were significantly decreased compared with those in control group （P 〈 0.05）. No significant differences in FPG, PPG and HbAlc were observed in both groups before and after treatment. Conclusion Low molecular heparin combined with valsartan is capable of reducing UAER in patients with early type - 2 DN.